We’re looking forward to ASN #KidneyWk 2025. Stop by booth 1142 to learn about our PAPP-A development program and ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease, which was recently granted FDA Fast Track Designation. https://t.co/lrJ1b2IVSQ